{"transactions":[{"id":3703925,"issuer":{"id":273,"kind":"organization","name":"OCULAR THERAPEUTIX, INC","symbol":"OCUL"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Reg. Affairs & Quality"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-04T18:29:10.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant."}],"balance_after":180000,"derivative":{"exercise_price":4.1,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001104659-19-000894","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1461612/000110465919000894/a4.xml","form_type":"4"}},{"id":3737563,"issuer":{"id":273,"kind":"organization","name":"OCULAR THERAPEUTIX, INC","symbol":"OCUL"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2018-12-10T16:15:33.000Z","date":"2018-12-06","kind":"purchase","acquired":true,"shares":17400,"price":5.76,"value":100224.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.79, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":42100,"source":{"system":"sec-edgar","filing":"0001104659-18-072100","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1461612/000110465918072100/a4.xml","form_type":"4"}},{"id":4079105,"issuer":{"id":273,"kind":"organization","name":"OCULAR THERAPEUTIX, INC","symbol":"OCUL"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-02T16:35:36.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":51100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant."}],"balance_after":51100,"derivative":{"exercise_price":5.47,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":51100},"source":{"system":"sec-edgar","filing":"0001104659-18-006262","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1461612/000110465918006262/a4.xml","form_type":"4"}},{"id":4137899,"issuer":{"id":273,"kind":"organization","name":"OCULAR THERAPEUTIX, INC","symbol":"OCUL"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-12-08T16:26:56.000Z","date":"2017-12-06","kind":"purchase","acquired":true,"shares":24700,"price":3.93,"value":97071.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.89 to $4.03, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":24700,"source":{"system":"sec-edgar","filing":"0001104659-17-072535","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1461612/000110465917072535/a4.xml","form_type":"4"}},{"id":4240068,"issuer":{"id":273,"kind":"organization","name":"OCULAR THERAPEUTIX, INC","symbol":"OCUL"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-08-08T18:02:27.000Z","date":"2017-08-07","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and 2.0833% of the shares vesting monthly thereafter."}],"balance_after":110000,"derivative":{"exercise_price":6.04,"expiration_date":"2027-08-06","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001104659-17-050339","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1461612/000110465917050339/a4.xml","form_type":"4"}},{"id":4443831,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Restricted Stock Units","published_at":"2017-02-16T14:15:50.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":3439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the \"RSU Payment\").  Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the \"RSU Payment\").  Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3439},"source":{"system":"sec-edgar","filing":"0000884731-17-000052","document":"wf-form4_148727253657061.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000052/wf-form4_148727253657061.xml","form_type":"4"}},{"id":4443830,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Restricted Stock Units","published_at":"2017-02-16T14:15:50.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":52666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":52666},"source":{"system":"sec-edgar","filing":"0000884731-17-000052","document":"wf-form4_148727253657061.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000052/wf-form4_148727253657061.xml","form_type":"4"}},{"id":4443829,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-02-16T14:15:50.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."}],"balance_after":0,"derivative":{"exercise_price":6.51,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000884731-17-000052","document":"wf-form4_148727253657061.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000052/wf-form4_148727253657061.xml","form_type":"4"}},{"id":4443828,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-02-16T14:15:50.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."}],"balance_after":0,"derivative":{"exercise_price":20.89,"underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0000884731-17-000052","document":"wf-form4_148727253657061.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000052/wf-form4_148727253657061.xml","form_type":"4"}},{"id":4443827,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-02-16T14:15:50.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the \"Offer\"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0."}],"balance_after":0,"derivative":{"exercise_price":15.05,"underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0000884731-17-000052","document":"wf-form4_148727253657061.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000052/wf-form4_148727253657061.xml","form_type":"4"}},{"id":4443826,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Common Stock","published_at":"2017-02-16T14:15:50.000Z","date":"2017-02-16","kind":"disposition_to_issuer","acquired":false,"shares":126352,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the \"Merger Agreement\"), between the Company, Takeda Pharmaceutical Company Limited (\"Takeda\") and Kiku Merger Co., Inc. (\"Purchaser\"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a \"Share\") was converted into the right to receive $24.00 in cash."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000884731-17-000052","document":"wf-form4_148727253657061.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000052/wf-form4_148727253657061.xml","form_type":"4"}},{"id":4465012,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Restricted Stock Units","published_at":"2017-02-07T16:58:35.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":3439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Stock Units (\"RSUs\") vest as to approximately one-third of the shares underlying the RSUs on each anniversary of the grant date; provided, however, that, subject to and effective upon the consummation of the transactions contemplated by that certain Agreement and Plan of Merger between ARIAD, Takeda Pharmaceutical Company Limited, and Kiku Merger Co., Inc., dated January 8, 2017, the RSUs shall be converted into the right to receive a cash amount equal to $24.00 for each share of common stock underlying the RSUs, payable in three annual installments on each anniversary of the grant date, subject to the terms of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"N/A"}],"balance_after":3439,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3439},"source":{"system":"sec-edgar","filing":"0000884731-17-000029","document":"wf-form4_148650470093986.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000029/wf-form4_148650470093986.xml","form_type":"4"}},{"id":4472032,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Restricted Stock Units","published_at":"2017-02-02T16:42:26.000Z","date":"2017-01-31","kind":"exercise","acquired":false,"shares":29333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were acquired upon the vesting of a Restricted Stock Unit previously granted on January 31, 2014."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units vest as approximately to one-third of the award on each of January 31, 2015, January 31, 2016 and January 31, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"N/A"}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":29333},"source":{"system":"sec-edgar","filing":"0000884731-17-000018","document":"wf-form4_148607172612766.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000018/wf-form4_148607172612766.xml","form_type":"4"}},{"id":4472031,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Common Stock","published_at":"2017-02-02T16:42:26.000Z","date":"2017-01-31","kind":"tax_withholding","acquired":false,"shares":14667,"price":23.8149,"value":349293.1383,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares were sold to satisfy the Company's tax withholding obligations pursuant to a Rule 10b5-1 plan adopted on June 15, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $23.795 to $23.83, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote."}],"balance_after":126352,"source":{"system":"sec-edgar","filing":"0000884731-17-000018","document":"wf-form4_148607172612766.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000018/wf-form4_148607172612766.xml","form_type":"4"}},{"id":4472030,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Common Stock","published_at":"2017-02-02T16:42:26.000Z","date":"2017-01-31","kind":"exercise","acquired":true,"shares":29333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were acquired upon the vesting of a Restricted Stock Unit previously granted on January 31, 2014."}],"balance_after":141019,"source":{"system":"sec-edgar","filing":"0000884731-17-000018","document":"wf-form4_148607172612766.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000018/wf-form4_148607172612766.xml","form_type":"4"}},{"id":4494401,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-01-10T18:17:46.000Z","date":"2017-01-09","kind":"exercise","acquired":false,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":7.82,"exercise_date":"2012-04-01","expiration_date":"2021-04-01","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0000884731-17-000002","document":"wf-form4_148409024894416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000002/wf-form4_148409024894416.xml","form_type":"4"}},{"id":4494400,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Common Stock","published_at":"2017-01-10T18:17:46.000Z","date":"2017-01-09","kind":"sale","acquired":false,"shares":32000,"price":23.78,"value":760960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan dated June 15, 2016"}],"balance_after":129404,"source":{"system":"sec-edgar","filing":"0000884731-17-000002","document":"wf-form4_148409024894416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000002/wf-form4_148409024894416.xml","form_type":"4"}},{"id":4494399,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Common Stock","published_at":"2017-01-10T18:17:46.000Z","date":"2017-01-09","kind":"exercise","acquired":true,"shares":32000,"price":7.82,"value":250240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were acquired from exercise of an outstanding stock option pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2016"}],"balance_after":161404,"source":{"system":"sec-edgar","filing":"0000884731-17-000002","document":"wf-form4_148409024894416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473117000002/wf-form4_148409024894416.xml","form_type":"4"}},{"id":4585343,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Common Stock","published_at":"2016-10-05T16:17:59.000Z","date":"2016-10-03","kind":"sale","acquired":false,"shares":47384,"price":13.4605,"value":637812.332,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a Rule 10b5-1 trading plan dated June 15, 2016"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  The shares were sold in multiple transactions at prices ranging from  $13.33 to $13.65 inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer,or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote."}],"balance_after":129404,"source":{"system":"sec-edgar","filing":"0000884731-16-000109","document":"wf-form4_147569866608040.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473116000109/wf-form4_147569866608040.xml","form_type":"4"}},{"id":4593725,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Performance stock unit","published_at":"2016-09-28T16:20:18.000Z","date":"2016-09-26","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance stock unit represents a right to receive done share of ARIAD common stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The performance stock units vest as to 50% of the award on 9/24/15 and 50% of the award on 9/26/2016."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The performance stock units vest as to 50% of the award on 9/24/15 and 50% of the award on 9/26/2016."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000884731-16-000107","document":"wf-form4_147509400503944.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473116000107/wf-form4_147509400503944.xml","form_type":"4"}},{"id":4593724,"issuer":{"id":134569,"kind":"organization","name":"ARIAD PHARMACEUTICALS INC"},"owners":[{"id":161272,"kind":"person","name":"Bollag Daniel M","position":1,"cik":"0001461612","reported_name":"Bollag Daniel M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Reg. Affairs & Quality"}}],"security":"Common Stock","published_at":"2016-09-28T16:20:18.000Z","date":"2016-09-26","kind":"exercise","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were acquired upon vesting of performance stock units awarded on March 19, 2013."}],"balance_after":176788,"source":{"system":"sec-edgar","filing":"0000884731-16-000107","document":"wf-form4_147509400503944.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/884731/000088473116000107/wf-form4_147509400503944.xml","form_type":"4"}}]}